ArticleMedicine2026
Research trends in olanzapine in treating schizophrenia from 2010 to 2026: A bibliometric analysis based on the Web of Science Core Collection.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchizophrenia is a severe chronic mental disorder, and olanzapine is widely used in its treatment. However, the expanding and heterogeneous literature on olanzapine in schizophrenia has not been comprehensively characterized from a bibliometric perspective. Therefore, this study aimed to systematically characterize the research landscape, hotspots, emerging frontiers, and knowledge evolution of olanzapine in the treatment of schizophrenia from 2010 to 2026.
methodsLiterature on olanzapine for the treatment of schizophrenia published between January 1, 2010, and March 29, 2026, was retrieved from the Web of Science Core Collection. CiteSpace (version 6.4.R2) and the Bibliometrix R package were used for bibliometric and visual analyses. Multiple bibliometric characteristics were analyzed, including publication trends, national and institutional distributions, core authors, journal distributions, co-citation of references, co-occurrence, clustering, keyword burst detection, and disciplinary biclustering.
resultsA total of 3943 valid publications were included. Annual publication volume generally increased over the study period, despite periodic minor fluctuations. The United States, China, and the United Kingdom accounted for the largest shares of publication output. From a bibliometric perspective, University College London stood out as a hub node within the collaboration network. Correll CU and Leucht S represented highly productive contributors. Schizophrenia Research was the most productive journal in terms of publication output. Keyword analysis indicated that the research focus gradually shifted from evaluation of drug efficacy and dosage-form development to metabolic risk management, personalized treatment, and real-world clinical research. Recent research primarily focused on population-based cohort studies, comparative evaluations of treatment efficacy, clinical practice guidelines, and treatment-related risk assessment.
conclusionResearch on olanzapine for the treatment of schizophrenia is ongoing. Current studies have shifted from efficacy verification to safety monitoring, with growing emphasis on population-based individualized dose adjustment, metabolic risk management, and large-sample comparative clinical studies for clinical guideline optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.